Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GYRE THERAPEUTICS, INC.GYRE · Entity 5247 | Director · President | May 27, 2025 | May 29, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GYRE THERAPEUTICS, INC.
Report date May 27, 2025 · Filed May 29, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 2,806,642 |
Reported balance
After 2025-05-27 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-05-27 · Sale · Disposed 2,000 · Balance 2,806,642 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F2: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $11.44. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 2,806,084 |
Reported balance
After 2025-05-28 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-05-28 · Sale · Disposed 558 · Balance 2,806,084 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F3: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.29. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.
F2: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $11.44. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.29. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 03, 2025 Filed Feb 4, 2025 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $11.47 | $22,940.00 |
DisclosureSEC source: 0001140361-25-002995 · form4.xml · nonDerivative · entry 2 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,887,138 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.26 to $11.66. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $11.51 | $23,020.00 |
DisclosureSEC source: 0001140361-25-002995 · form4.xml · nonDerivative · entry 1 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,889,138 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.36 to $11.77. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 30, 2025 Filed Jan 31, 2025 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $11.37 | $22,740.00 |
DisclosureSEC source: 0001140361-25-002702 · form4.xml · nonDerivative · entry 2 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,891,138 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.15 to $11.80. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 29, 2025 Filed Jan 31, 2025 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $11.43 | $22,860.00 |
DisclosureSEC source: 0001140361-25-002702 · form4.xml · nonDerivative · entry 1 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,893,138 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.28 to $11.58. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 28, 2025 Filed Jan 29, 2025 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $11.51 | $23,020.00 |
DisclosureSEC source: 0001140361-25-002340 · form4.xml · nonDerivative · entry 2 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,895,138 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.25 to $11.78. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $11.18 | $22,360.00 |
DisclosureSEC source: 0001140361-25-002340 · form4.xml · nonDerivative · entry 1 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,897,138 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.01 to $11.37. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 24, 2025 Filed Jan 27, 2025 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $10.89 | $21,780.00 |
DisclosureSEC source: 0001140361-25-002062 · form4.xml · nonDerivative · entry 2 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,899,138 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.51 to $11.21. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $10.49 | $20,980.00 |
DisclosureSEC source: 0001140361-25-002062 · form4.xml · nonDerivative · entry 1 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,901,138 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.42 to $10.74. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 22, 2025 Filed Jan 24, 2025 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $10.63 | $21,260.00 |
DisclosureSEC source: 0001140361-25-001891 · form4.xml · nonDerivative · entry 2 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,903,138 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.55 to $10.79. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 21, 2025 Filed Jan 24, 2025 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $10.85 | $21,700.00 |
DisclosureSEC source: 0001140361-25-001891 · form4.xml · nonDerivative · entry 1 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,905,138 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.60 to $11.35. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 17, 2025 Filed Jan 21, 2025 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $10.72 | $21,440.00 |
DisclosureSEC source: 0001140361-25-001526 · form4.xml · nonDerivative · entry 2 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,907,138 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.60 to $11.93. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 16, 2025 Filed Jan 21, 2025 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $10.71 | $21,420.00 |
DisclosureSEC source: 0001140361-25-001526 · form4.xml · nonDerivative · entry 1 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,909,138 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.60 to $10.91. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 15, 2025 Filed Jan 16, 2025 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $10.85 | $21,700.00 |
DisclosureSEC source: 0001140361-25-001283 · form4.xml · nonDerivative · entry 2 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,911,138 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.74 to $11.08. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 14, 2025 Filed Jan 16, 2025 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $10.39 | $20,780.00 |
DisclosureSEC source: 0001140361-25-001283 · form4.xml · nonDerivative · entry 1 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,913,138 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.13 to $10.60. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 13, 2025 Filed Jan 14, 2025 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 56 | $10.10 | $565.60 |
DisclosureSEC source: 0001140361-25-001059 · form4.xml · nonDerivative · entry 2 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,915,138 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.20. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 10, 2025 Filed Jan 14, 2025 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 1,057 | $10.02 | $10,591.14 |
DisclosureSEC source: 0001140361-25-001059 · form4.xml · nonDerivative · entry 1 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,915,194 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.38. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 07, 2025 Filed Jan 8, 2025 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 1,275 | $10.02 | $12,775.50 |
DisclosureSEC source: 0001140361-25-000610 · form4.xml · nonDerivative · entry 2 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,916,251 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.24. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 06, 2025 Filed Jan 8, 2025 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 941 | $10.16 | $9,560.56 |
DisclosureSEC source: 0001140361-25-000610 · form4.xml · nonDerivative · entry 1 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,917,526 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.76. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 03, 2025 Filed Jan 6, 2025 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 1,167 | $11.03 | $12,872.01 |
DisclosureSEC source: 0001140361-25-000339 · form4.xml · nonDerivative · entry 2 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,919,300 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.73 to $11.70. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 03, 2025 Filed Jan 10, 2025 21:01 UTC Amendment | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 833 | $11.85 | $9,871.05 |
DisclosureSEC source: 0001140361-25-000827 · form4.xml · nonDerivative · entry 1 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,918,467 F1 · date: This Form 4 amends the Form 4 filed on January 6, 2025 to reflect the correct transaction date as of January 3, 2025. The original filing incorrectly reported the transaction date as of January 3, 2024. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $12.40 | $24,800.00 |
DisclosureSEC source: 0001140361-25-000339 · form4.xml · nonDerivative · entry 1 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,920,467 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.99 to $12.80. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 31, 2024 Filed Jan 2, 2025 21:06 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $12.30 | $24,600.00 |
DisclosureSEC source: 0001140361-25-000074 · form4.xml · nonDerivative · entry 2 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,922,467 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.01 to $12.76. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 30, 2024 Filed Jan 2, 2025 21:06 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $12.50 | $25,000.00 |
DisclosureSEC source: 0001140361-25-000074 · form4.xml · nonDerivative · entry 1 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,924,467 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.07 to $12.75. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 27, 2024 Filed Dec 30, 2024 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $12.58 | $25,160.00 |
DisclosureSEC source: 0001140361-24-050588 · form4.xml · nonDerivative · entry 3 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,926,467 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F4 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.40 to $13.14. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 26, 2024 Filed Dec 30, 2024 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 356 | $13.05 | $4,645.80 |
DisclosureSEC source: 0001140361-24-050588 · form4.xml · nonDerivative · entry 2 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,928,467 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $13.00 to $13.13. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 26, 2024 Filed Dec 30, 2024 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 1,644 | $12.62 | $20,747.28 |
DisclosureSEC source: 0001140361-24-050588 · form4.xml · nonDerivative · entry 1 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,928,823 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.97. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 24, 2024 Filed Dec 26, 2024 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $11.93 | $23,860.00 |
DisclosureSEC source: 0001140361-24-050413 · form4.xml · nonDerivative · entry 3 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,930,467 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F4 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.76 to $12.09. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 23, 2024 Filed Dec 26, 2024 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 296 | $12.44 | $3,682.24 |
DisclosureSEC source: 0001140361-24-050413 · form4.xml · nonDerivative · entry 2 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,932,467 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.41 to $12.48. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 23, 2024 Filed Dec 26, 2024 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 1,704 | $12.24 | $20,856.96 |
DisclosureSEC source: 0001140361-24-050413 · form4.xml · nonDerivative · entry 1 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,932,763 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.40 to $12.39. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 20, 2024 Filed Dec 23, 2024 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $10.90 | $21,800.00 |
DisclosureSEC source: 0001140361-24-050250 · form4.xml · nonDerivative · entry 2 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,934,467 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.39 to $11.11. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 19, 2024 Filed Dec 23, 2024 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 2,000 | $10.82 | $21,640.00 |
DisclosureSEC source: 0001140361-24-050250 · form4.xml · nonDerivative · entry 1 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,936,467 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.61 to $11.35. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 429 | $12.11 | $5,195.19 |
DisclosureSEC source: 0001140361-24-049939 · form4.xml · nonDerivative · entry 4 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,938,467 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F5 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.70 to $12.46. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 1,571 | $11.17 | $17,548.07 |
DisclosureSEC source: 0001140361-24-049939 · form4.xml · nonDerivative · entry 3 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,938,896 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F4 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.70 to $11.69. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 17, 2024 Filed Dec 19, 2024 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 788 | $11.23 | $8,849.24 |
DisclosureSEC source: 0001140361-24-049939 · form4.xml · nonDerivative · entry 2 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,940,467 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.10 to $11.37. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 17, 2024 Filed Dec 19, 2024 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 1,212 | $10.94 | $13,259.28 |
DisclosureSEC source: 0001140361-24-049939 · form4.xml · nonDerivative · entry 1 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,941,255 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.10 to $11.095. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| August 14, 2024 Filed Aug 17, 2024 01:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 26,000 | $0.00 Strike: $9.98 | $0.00 |
DisclosureSEC source: 0001140361-24-037709 · form4.xml · derivative · entry 1 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2034-08-14 F1 · derivative.exercise_date: This option represents a right to purchase a total of 26,000 shares of the Issuer's common stock, which will vest in 12 equal monthly installments through August 14, 2025, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| January 03, 2024 Filed Jan 6, 2025 21:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 833 | $11.85 | $9,871.05 |
DisclosureSEC source: 0001140361-25-000339 · form4.xml · nonDerivative · entry 3 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 2,918,467 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024. F4 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.73 to $12.27. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 20, 2023 Filed Nov 23, 2023 00:40 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 4,510,047 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001140361-23-054518 · form4.xml · derivative · entry 1 Ma Songjiang · CIK 0001985547 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,510,047 Underlying: Common Stock · 4,510,047 shares Expires 2030-10-31 F1 · derivative.exercise_price: Beijing Continent Pharmaceuticals Co., Ltd, a company organized under the laws of the People's Republic of China ("Beijing Continent"), terminated its 2021 Stock Incentive Plan (the "2021 Plan") and each option (a "BC Option") to purchase common shares of Beijing Continent outstanding under the 2021 Plan was terminated and replaced with options granted pursuant to a sub-plan for Chinese participants under the Issuer's 2023 Omnibus Incentive Plan that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan. F1 · derivative.exercise_date: Beijing Continent Pharmaceuticals Co., Ltd, a company organized under the laws of the People's Republic of China ("Beijing Continent"), terminated its 2021 Stock Incentive Plan (the "2021 Plan") and each option (a "BC Option") to purchase common shares of Beijing Continent outstanding under the 2021 Plan was terminated and replaced with options granted pursuant to a sub-plan for Chinese participants under the Issuer's 2023 Omnibus Incentive Plan that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan. F2 · derivative.exercise_date: These options are vested in full. F1 · derivative.expiration_date: Beijing Continent Pharmaceuticals Co., Ltd, a company organized under the laws of the People's Republic of China ("Beijing Continent"), terminated its 2021 Stock Incentive Plan (the "2021 Plan") and each option (a "BC Option") to purchase common shares of Beijing Continent outstanding under the 2021 Plan was terminated and replaced with options granted pursuant to a sub-plan for Chinese participants under the Issuer's 2023 Omnibus Incentive Plan that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.